Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Medtronic, Inc.    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Studies Fail to Back Medtronic Drug Claims

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2013 | 11:45pm CEST

Two independent studies found a controversial Medtronic Inc. (>> Medtronic, Inc.) bone-growth product for spine surgeries was no better than a traditional operation. The studies were the result of a two-year experiment in lifting the veil on industry-sponsored trial data.

Medtronic's product, called Infuse, has been plagued by allegations that doctors who wrote key studies backing the technology received millions of dollars in royalties and fees related to other work and may have understated risks.

The company took the unusual step of handing over detailed trial data on Infuse to a team of Yale University experts, along with a $2.5 million grant. Yale hired outside researchers to analyze the data.

Overall complication rates for the back-pain surgeries were similar regardless of whether Infuse was used, according to the studies, published in the Annals of Internal Medicine. One of the studies, by Oregon Health & Science University researchers, linked Infuse to increased cancer rates after two years.

But cancer risks remain small, the researchers said, and the other study, by researchers at the University of York in the U.K., didn't detect a cancer link.

"We found the product offered no additional benefits beyond the normal benefits" of the spine surgery, said Rongwei Fu, the lead author of the Oregon study. Coupled with the increased cancer risk, the study said, it was difficult to identify "clear indications" for using the product.

"We found a lot of reporting bias in [Medtronic's] published papers that tends to overstate the benefits and downplayed the risks," Dr. Fu said, citing, for example, failing to include certain complications.

In the traditional procedure, surgeons extract bone from patients' pelvises and use it to stabilize vertebrae. Infuse, a genetically engineered protein, prompts bone growth, eliminating the need to harvest the extra bone. The hope was that would reduce complication rates and limit pain.

Medtronic said it believed the research supported Infuse's Food and Drug Administration-approved uses in a spine procedure. The product is widely used off-label for other procedures, including in the neck.

Researchers heralded Medtronic's move to voluntarily release its data cache as a transparency milestone. Medical journals often publish research financed by drug and medical device makers, but many industry-funded studies are never aired. Researchers and physicians worry that negative results are buried and risks understated to make products look better.

"We have a health-care system that's built on evidence that's incomplete and not missing at random," said Harlan Krumholz, the Yale cardiologist who devised the Yale Open Data Access Project, or Yoda, and forged the Medtronic deal.

Dr. Krumholz praised Medtronic for "setting a precedent" by providing the data.

Medtronic said it would continue to participate in such efforts. Opening access to data "for physicians to make informed therapy decisions .. makes a lot of sense to us," said Chris O'Connell, the Medtronic group president overseeing the unit that makes Infuse.

The project comes amid broader pressure to release trial data. Since 2007, firms have been required to disclose the existence of clinical trials to a U.S. government website, ClinicalTrials.gov. But they aren't required to publicly disclose results.

Last month, GlaxoSmithKline PLC (GSK, GSK.LN) offered outside researchers a new process to gain access to some of its trial data. "There's been an appetite to have access to this for quite a period of time," said Perry Nisen, the U.K. drug maker's senior vice president for science and innovation.

Dr. Nisen waved off concerns that rivals could use such data to call into question the company's products, saying, "the truth has to prevail."

More data access could allow outside researchers to track the effectiveness of specific drugs in certain subgroups of patients, such as diabetics or older people, and to compare treatments to see which are most effective, said researchers such as Deborah Schrag, an oncologist at the Dana-Farber Cancer Institute in Boston.

In Medtronic's case, transparency didn't immediately provide clarity.

Medtronic's Mr. O'Connell said the studies reinforce "what we've always believed: that Infuse is an important option for many patients." More than one million patients have received the product, he said, adding that the company would continue to seek FDA approval to market it for other uses.

By contrast, some doctors expressed reservations. "I will probably use [Infuse] seldom in my own practice until I get better and clearer data in terms of what maybe some of these potential complications are," especially cancer risks, said Michael Schafer, an orthopedic surgeon at Northwestern Medicine in Chicago.

Eugene Carragee, a Stanford University professor of orthopedic surgery and the author of a 2011 Spine Journal article that suggested Medtronic's trials understated risks and sparked much of the Infuse controversy, said he hoped the results further limited Infuse use, which has declined in recent years.

The Senate Finance Committee investigated whether Medtronic payments to its researchers influenced the results they reported. A Senate report in October alleged that Medtronic paid those researchers a total of $210 million for company-related work, largely in royalties for other products.

Medtronic said it has limited the role of doctors who earn royalties for its products in conducting related research.

Write to Christopher Weaver at christopher.weaver@wsj.com

(CORRECTION: This article was corrected because the headline mischaracterized Medtronic's bone-growth product Infuse as a drug.)

Stocks mentioned in the article : Medtronic, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDTRONIC, INC.
07/22 WESTINGHOUSE AIR BRAKE TECHNOLOGIES : Linda harty joins wabtec board of director..
07/21 MEDTRONIC : Federal Contracts Awarded to Companies in Minnesota (July 21)
07/21 MEDTRONIC : Contract award - 65-- defibrillator-medtronic-5066q8799
07/21 With acquisition pending, St. Jude Medical's rivals 'licking their lips,' ana..
07/20 MEDTRONIC : Medtronics New Guardian Connect Smartphone Powered Glucometer
07/20 MEDTRONIC : Receives First-Ever FDA Clearance for Cement-Augmented Pedicle Screw..
07/20DJSt. Jude Medical Logs Double-Digit Sales Growth
07/20 MEDTRONIC : Assigned Patent
07/19 MEDTRONIC : Receives FDA Approval for Two-Level Prestige LP Cervical Disc Proced..
07/19 MEDTRONIC : Expands Continuous Glucose Monitoring (CGM) Solutions for People wit..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
07/22DJDEXCOM : Shares Rise After FDA Panel Vote
07/21DJSTRYKER : Raises Annual Guidance, but Current Quarter's View Misses Targets
07/20DJSt. Jude Medical Logs Double-Digit Sales Growth -- Update
07/20DJAbbott Labs Profit Tops Views
07/20DJABBOTT LABORATORIES : Labs Profit Tops Views
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
2015 DIVIDEND INCOME UPDATE : January 2015
2015 FDA clears Medtronic transcatheter heart valve
2015 Dividend Aristocrats And A Fundamental Principle Of Dividend Growth Investing
2015 Boston Scientific Awaits Court Decision
2015 The DGI 'Factual 48' Versus 'The Favored 44'
Advertisement
Financials ($)
Sales 2017 29 929 M
EBIT 2017 7 976 M
Net income 2017 5 375 M
Debt 2017 22 670 M
Yield 2017 1,98%
P/E ratio 2017 24,05
P/E ratio 2018 20,96
EV / Sales 2017 4,82x
EV / Sales 2018 4,49x
Capitalization 121 481 M
More Financials
Chart MEDTRONIC, INC.
Duration : Period :
Medtronic, Inc. Technical Analysis Chart | US5850551061 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 90,7 $
Spread / Average Target 4,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Omar S. Ishrak Chairman & Chief Executive Officer
Gary Lee Ellis EVP-Global Operations & Information Technology
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Chief Scientific, Clinical & Regulatory Officer
Richard H. Anderson Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC, INC.0.78%121 481
MEDTRONIC PLC13.23%121 481
BAXTER INTERNATIONAL I..21.42%25 581
ZIMMER BIOMET HOLDINGS..21.34%24 856
C R BARD INC21.41%16 863
TERUMO CORP25.74%16 678
More Results